181 related articles for article (PubMed ID: 37328788)
21. Identification of endoplasmic reticulum stress-related signature characterizes the tumor microenvironment and predicts prognosis in lung adenocarcinoma.
Wan L; Chen Z; Yang J; Wu G; Xu Y; Cui J; Zhao X
Sci Rep; 2023 Nov; 13(1):19462. PubMed ID: 37945620
[TBL] [Abstract][Full Text] [Related]
22. Construction and analysis of a novel ferroptosis-related gene signature predicting prognosis in lung adenocarcinoma.
Zhou J; Wang X; Li Z; Jiang R
FEBS Open Bio; 2021 Nov; 11(11):3005-3018. PubMed ID: 34499810
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of endoplasmic reticulum stress-related eight-gene signature for predicting the overall survival of lung adenocarcinoma.
Lin L; Zhang W
Transl Cancer Res; 2022 Jul; 11(7):1909-1924. PubMed ID: 35966313
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
25. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
Yang Q; Zhu W; Gong H
Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma.
Guo Z; Hu L; Wang Q; Wang Y; Liu XP; Chen C; Li S; Hu W
Curr Oncol; 2023 Feb; 30(3):2845-2861. PubMed ID: 36975430
[TBL] [Abstract][Full Text] [Related]
27. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
[TBL] [Abstract][Full Text] [Related]
28. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
29. Prognostic signature of lung adenocarcinoma based on stem cell-related genes.
Huang Z; Shi M; Zhou H; Wang J; Zhang HJ; Shi J-
Sci Rep; 2021 Jan; 11(1):1687. PubMed ID: 33462260
[TBL] [Abstract][Full Text] [Related]
30. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of an endoplasmic reticulum stress long non-coding RNA signature for the prognosis and immune landscape prediction of patients with lung adenocarcinoma.
Zeng J; Wu Z; Luo M; Xu X; Bai W; Xie G; Chen Q; Liang D; Xu Z; Chen M; Xie J
Front Genet; 2023; 14():1024444. PubMed ID: 36891153
[No Abstract] [Full Text] [Related]
32. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
34. Novel Circulating Tumour Cell-Related Risk Model Indicates Prognosis and Immune Infiltration in Lung Adenocarcinoma.
Liang L; Liu Y; Jiang S; Huang J; He H; Shen L; Cong L; Jiang Y
J Immunol Res; 2022; 2022():6521290. PubMed ID: 35677538
[TBL] [Abstract][Full Text] [Related]
35. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.
Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X
Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526
[TBL] [Abstract][Full Text] [Related]
36. A New Prognostic Indicator of Immune Microenvironment and Therapeutic Response in Lung Adenocarcinoma Based on Peroxisome-Related Genes.
Xiong Z; Zhang L; Fan W
J Immunol Res; 2022; 2022():6084589. PubMed ID: 35935579
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of the association between tumor-infiltrating immune cells and the prognosis of lung adenocarcinoma.
Pan Y; Sha Y; Wang H; Zhuang H; Ren X; Zhu X; Wei X
J Cancer Res Ther; 2020; 16(2):320-326. PubMed ID: 32474519
[TBL] [Abstract][Full Text] [Related]
38. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
39. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
40. A seven-gene prognostic model related to immune checkpoint PD-1 revealing overall survival in patients with lung adenocarcinoma.
Niu W; Jiang L
Math Biosci Eng; 2021 Jul; 18(5):6136-6154. PubMed ID: 34517527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
